TW201029583A - A nutritional composition comprising probiotics and improving sleep patterns - Google Patents
A nutritional composition comprising probiotics and improving sleep patterns Download PDFInfo
- Publication number
- TW201029583A TW201029583A TW098137248A TW98137248A TW201029583A TW 201029583 A TW201029583 A TW 201029583A TW 098137248 A TW098137248 A TW 098137248A TW 98137248 A TW98137248 A TW 98137248A TW 201029583 A TW201029583 A TW 201029583A
- Authority
- TW
- Taiwan
- Prior art keywords
- sleep
- nutritional composition
- infant formula
- cfu
- probiotic
- Prior art date
Links
- 230000007958 sleep Effects 0.000 title claims abstract description 76
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 239000006041 probiotic Substances 0.000 title claims abstract description 53
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 53
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 30
- 230000000529 probiotic effect Effects 0.000 claims abstract description 32
- 208000019116 sleep disease Diseases 0.000 claims abstract description 24
- 241001465754 Metazoa Species 0.000 claims abstract description 21
- 230000001580 bacterial effect Effects 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 16
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 6
- 235000013350 formula milk Nutrition 0.000 claims description 40
- 150000001720 carbohydrates Chemical class 0.000 claims description 24
- 235000014633 carbohydrates Nutrition 0.000 claims description 24
- 241000894006 Bacteria Species 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 15
- 241000186660 Lactobacillus Species 0.000 claims description 13
- 241000209094 Oryza Species 0.000 claims description 12
- 235000007164 Oryza sativa Nutrition 0.000 claims description 12
- 229940039696 lactobacillus Drugs 0.000 claims description 12
- 235000009566 rice Nutrition 0.000 claims description 12
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 11
- 239000008267 milk Substances 0.000 claims description 11
- 239000013589 supplement Substances 0.000 claims description 11
- 206010022437 insomnia Diseases 0.000 claims description 10
- 235000013336 milk Nutrition 0.000 claims description 10
- 210000004080 milk Anatomy 0.000 claims description 10
- 208000019901 Anxiety disease Diseases 0.000 claims description 8
- 241000186000 Bifidobacterium Species 0.000 claims description 7
- 230000036506 anxiety Effects 0.000 claims description 7
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 6
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 6
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 6
- 235000009508 confectionery Nutrition 0.000 claims description 6
- 241000894007 species Species 0.000 claims description 5
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 4
- 206010062519 Poor quality sleep Diseases 0.000 claims description 4
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 208000028399 Critical Illness Diseases 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 208000002720 Malnutrition Diseases 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 235000008452 baby food Nutrition 0.000 claims description 3
- 235000013339 cereals Nutrition 0.000 claims description 3
- 235000013611 frozen food Nutrition 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 235000020256 human milk Nutrition 0.000 claims description 3
- 210000004251 human milk Anatomy 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 239000006194 liquid suspension Substances 0.000 claims description 3
- 230000001071 malnutrition Effects 0.000 claims description 3
- 235000000824 malnutrition Nutrition 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- 208000015380 nutritional deficiency disease Diseases 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 235000014347 soups Nutrition 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 235000013618 yogurt Nutrition 0.000 claims description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 2
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 2
- 235000015496 breakfast cereal Nutrition 0.000 claims description 2
- 230000001332 colony forming effect Effects 0.000 claims description 2
- 235000011850 desserts Nutrition 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 206010061958 Food Intolerance Diseases 0.000 claims 2
- 206010036790 Productive cough Diseases 0.000 claims 2
- 208000037976 chronic inflammation Diseases 0.000 claims 2
- 230000006020 chronic inflammation Effects 0.000 claims 2
- 235000015872 dietary supplement Nutrition 0.000 claims 2
- 230000035764 nutrition Effects 0.000 claims 2
- 210000003802 sputum Anatomy 0.000 claims 2
- 208000024794 sputum Diseases 0.000 claims 2
- 241000233866 Fungi Species 0.000 claims 1
- 241000237502 Ostreidae Species 0.000 claims 1
- 235000021152 breakfast Nutrition 0.000 claims 1
- 235000020299 breve Nutrition 0.000 claims 1
- 235000013353 coffee beverage Nutrition 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 235000020636 oyster Nutrition 0.000 claims 1
- 239000002689 soil Substances 0.000 claims 1
- 208000022925 sleep disturbance Diseases 0.000 abstract description 5
- 230000035800 maturation Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- 108010046377 Whey Proteins Proteins 0.000 description 16
- 230000003860 sleep quality Effects 0.000 description 16
- 229940088594 vitamin Drugs 0.000 description 16
- 229930003231 vitamin Natural products 0.000 description 16
- 235000013343 vitamin Nutrition 0.000 description 16
- 239000011782 vitamin Substances 0.000 description 16
- 102000007544 Whey Proteins Human genes 0.000 description 15
- 239000005862 Whey Substances 0.000 description 13
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 11
- 229910052500 inorganic mineral Inorganic materials 0.000 description 11
- 239000011707 mineral Substances 0.000 description 11
- 235000010755 mineral Nutrition 0.000 description 11
- 235000019197 fats Nutrition 0.000 description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 10
- 241000186604 Lactobacillus reuteri Species 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 230000037007 arousal Effects 0.000 description 8
- 229940001882 lactobacillus reuteri Drugs 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 229920001542 oligosaccharide Polymers 0.000 description 8
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 8
- 229910052761 rare earth metal Inorganic materials 0.000 description 8
- 150000003722 vitamin derivatives Chemical class 0.000 description 8
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 7
- 150000003271 galactooligosaccharides Chemical class 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000035882 stress Effects 0.000 description 7
- 230000006872 improvement Effects 0.000 description 6
- 239000011777 magnesium Substances 0.000 description 6
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 235000020778 linoleic acid Nutrition 0.000 description 5
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 5
- 150000002482 oligosaccharides Chemical class 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- -1 sialic acid oligosaccharide Chemical class 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- 241001608472 Bifidobacterium longum Species 0.000 description 4
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 101000998897 Homo sapiens Serine protease HTRA3 Proteins 0.000 description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 102100033197 Serine protease HTRA3 Human genes 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 229940009291 bifidobacterium longum Drugs 0.000 description 4
- 229940071604 biogaia Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 239000005018 casein Substances 0.000 description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 4
- 235000021240 caseins Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 229960000304 folic acid Drugs 0.000 description 4
- 235000019152 folic acid Nutrition 0.000 description 4
- 239000011724 folic acid Substances 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 229940055726 pantothenic acid Drugs 0.000 description 4
- 235000019161 pantothenic acid Nutrition 0.000 description 4
- 239000011713 pantothenic acid Substances 0.000 description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 4
- 235000019155 vitamin A Nutrition 0.000 description 4
- 239000011719 vitamin A Substances 0.000 description 4
- 235000019158 vitamin B6 Nutrition 0.000 description 4
- 239000011726 vitamin B6 Substances 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 229940045997 vitamin a Drugs 0.000 description 4
- 229940011671 vitamin b6 Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 241000186012 Bifidobacterium breve Species 0.000 description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 101150056950 Ntrk2 gene Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- 229930003471 Vitamin B2 Natural products 0.000 description 3
- 229930003316 Vitamin D Natural products 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 3
- 229940107187 fructooligosaccharide Drugs 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229960002477 riboflavin Drugs 0.000 description 3
- 208000020685 sleep-wake disease Diseases 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 235000019164 vitamin B2 Nutrition 0.000 description 3
- 239000011716 vitamin B2 Substances 0.000 description 3
- 235000019166 vitamin D Nutrition 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 description 3
- 229940046008 vitamin d Drugs 0.000 description 3
- 235000021119 whey protein Nutrition 0.000 description 3
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000002881 Colic Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 2
- 241000194036 Lactococcus Species 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 108090000742 Neurotrophin 3 Proteins 0.000 description 2
- 102100029268 Neurotrophin-3 Human genes 0.000 description 2
- 102000003683 Neurotrophin-4 Human genes 0.000 description 2
- 108090000099 Neurotrophin-4 Proteins 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- FVVCFHXLWDDRHG-UHFFFAOYSA-N Nigellamose Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)O1 FVVCFHXLWDDRHG-UHFFFAOYSA-N 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000002567 electromyography Methods 0.000 description 2
- FVVCFHXLWDDRHG-KKNDGLDKSA-N erlose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-KKNDGLDKSA-N 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960000511 lactulose Drugs 0.000 description 2
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 2
- 229910052746 lanthanum Inorganic materials 0.000 description 2
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229940032018 neurotrophin 3 Drugs 0.000 description 2
- 229940097998 neurotrophin 4 Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- PFFIDZXUXFLSSR-UHFFFAOYSA-N 1-methyl-N-[2-(4-methylpentan-2-yl)-3-thienyl]-3-(trifluoromethyl)pyrazole-4-carboxamide Chemical compound S1C=CC(NC(=O)C=2C(=NN(C)C=2)C(F)(F)F)=C1C(C)CC(C)C PFFIDZXUXFLSSR-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000149420 Bothrometopus brevis Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000235035 Debaryomyces Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 241001135786 Lactobacillus cerevisiae Species 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 229920001732 Lignosulfonate Polymers 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 238000010793 Steam injection (oil industry) Methods 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 229920001938 Vegetable gum Polymers 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 241000235015 Yarrowia lipolytica Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 241000235017 Zygosaccharomyces Species 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000037328 acute stress Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940125713 antianxiety drug Drugs 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007996 neuronal plasticity Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000011257 shell material Substances 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 102000015534 trkB Receptor Human genes 0.000 description 1
- 108010064880 trkB Receptor Proteins 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Anesthesiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
201029583 六、發明說明: 【發明所屬之技術領域】 本發明係關於—種益生細菌菌株之用途,其用於在嬰兒 . &幼小兒童中改善睡眠模式成熟及減少夜晚失眠及/或在 . ㈣年齡之經歷睡眠變化之人類或動物中減少睡眠障礙及 改善睡眠品質。 【先前技術】 φ 在生命之任何階段都可觀察到睡眠障礙。此等障礙通常 以開始及維持睡眠之能力降低及較深、較具恢復性之睡眠 的比例降低為特徵。經歷彼等變化之個體的生活品質實質 - 上受到了損害。 嬰兒睡眠在生命之第一個月内通常會變化以遵循晝夜節 律,其中睡眠在晚上持續一段較長之連續時間,且類似 地,睡眠狀態自在出生時於REM(活動)與]^11£]^(安靜)睡眠 之間平等分布變為至8個月大時三分之一 REM及三分之二 φ NREM。若無法在嬰兒期成功地協調此等變化,則亦會對 兒童之睡眠模式產生持久影響。 嬰兒及兒童中最常見之睡眠障礙為與失眠(亦即難以在 • 就寢時間平靜下來或無法無間斷地睡一整夜)有關者。據 . 估計,此等障礙影響著15%至35%的年齡不到24個月之嬰 兒(France等人 ’「Infant Sleep Disturbance: Description 〇f a problem behaviour process」,Sleep Medicine Reviews, 第3卷,第4期,第265-280頁,1999)。嬰兒及兒童睡眠障 礙不可避免地會引起父母睡眠障礙與壓力,此會導致不當 144353.doc 201029583 的兒童-父母相互作用,繼而加重嬰兒及兒童症狀,從而 引起惡性循環。 許多涉及嬰兒睡眠障礙之文獻聚焦於心理因素,諸如母 親之產前與產後壓力及高度焦慮。例如,Field及同事研究 了孕婦在扭娠之第二個及第三個三月期(trimester)期間之 睡眠障礙、抑鬱、焦慮及憤怒與其新生嬰兒之睡眠模式之 間的關係。他們觀察到抑鬱母親所生之嬰兒亦會經歷睡眠 障礙,包括深度睡眠時間較少及不定型(紊亂)睡眠時間較 多(Field 等人,「sleep disturbances in depressed pregnant women and their newborns」, Infant Behavior and Development 30 (2007) 127-133) ° 此等及類似之觀察結果使兒科醫師當被嬰兒及兒童之父 母詢問有關嬰兒睡眠障礙之問題時集中於推薦行為管理技 術,諸如確立一貫的就寢時間慣例、逐漸使就寢時間移至 較早的時間或逐漸減少對於覺醒的注意力。該等措施可為 有效的,但常常難以為父母所用。 正常變老伴隨有睡眠品質、睡眠量及睡眠結構之變化。 具體而言,健康年長者開始及維持睡眠之能力似乎有可量 測之降低,並伴以較深、較具恢復性之NREM睡眠比例的 降低(Espiritu JR. Aging-related sleep changes, Clin Geriatr Med. 2008 24(1):1-14)。 急性及慢性壓力、焦慮及抑鬱通常導致任何年齡段之睡 眠模式變化及失眠症(Chorney DB,Detweiler MF,Morris TL, Kuhn BR, The interplay of sleep disturbance, anxiety, 144353.doc 201029583 and depression in children, J Pediatr Psych〇1 2〇〇8 33(4):339-48 ; LeBlanc M, Merette C, Savard J, Ivers H, Baillargeon L, Morin CM, Incidence and risk factors of * insomnia in a population-based sample. Sleep. 2009 . 32(8):1027-37) ° 偶爾及在極端情況下,可開立抗焦慮藥物(例如苯并二 氮呼)之藥方。然而,此等藥物之功效為可變的,難以確 • 立恰當之劑量且有害副作用之風險較高。在任何情況下, 特別對於嬰兒及幼小卩童而t,-般反對開立此類強效藥 物之藥方。 根據上述可得知,仍需要替代性方法以在生命的不同階 段減少睡眠障礙且改善睡眠模式。 【發明内容】 本發明者意外地發現,投與一種益生細菌菌株可在經歷 睡眠變化及/或失眠症之個體中改善睡眠品質且減少失眠 嚳 #生次數’且具體而言,可在嬰兒及幼小兒童中誘發較成 熟之睡眠模式。因此,在模擬由具有不良或不成熟之睡眠 时質之嬰兒及兒童以及由經歷睡眠變化之成人所經歷的睡 ' 眠變化之動物模型中’益生菌之投與藉由減少活動睡眠 ' (REM)之時間、增加安靜睡眠(NREM)之時間及減少覺醒發 生之次數來完全使睡眠模式正常化。 因此’本發明提供一種益生、細菌菌株之用途,其用於製 k用以在女兒及幼小兒童中誘發較成熟之睡眠模式及用於 在任何年齡段減少睡眠障礙及/或改善睡眠模式的藥物或 144353.doc 201029583 治療性營養組合物。「較成熟」在此處係指睡眠模式類似 於或接近於未經歷睡眠週期延遲成熟且因此未經歷睡眠障 礙之個體之睡眠模式。「較成熟之睡眠模式」的特徵在於 晚上持續較長之連續睡眠時間,此係與活動(REM)睡眠持 續時間之減少及安靜(NREM)睡眠持續時間之增加有關。 該REM及該NREM為睡眠模式成熟之良好指標。 本發明延伸出一種在嬰兒及幼小兒童中誘發較成熟之睡 眠模式及在任何年齡段減少睡眠障礙及/或改善睡眠模式 之方法,其包含向有需要之個體投與治療量之益生細菌菌 株。 BDNF(源於腦之神經營養因子)為一種可促進位於中樞 神經系統中或與中樞神經系統直接相連之神經元群體存活 的蛋白質。其為可影響神經元細胞及非神經元細胞增殖、 分化、存活及死亡之具有1 5種多肽生長因子之獨特家族中 的一員。BDNF及其他神經營養生長因子(例如NGF(神經生 長因子)、NT-3(神經營養蛋白-3)及NT-4(神經營養蛋白-4)) 對於神經系統之健康及良好狀態係必不可少的,且除了其 在細胞存活中之作用以外,還介導諸如學習、記憶、行為 之高級活動。已在動物模型中證實腦中之高BDNF含量可 增加自然睡眠及NRE1V[持續時間(Kushikata, Am J Physiol, 1999),而阻斷BDNF之TrkB受體會擾亂睡眠模式(Faraguna 等人,J Neurosci,2008)。根據未公布之資料,本發明者 意識到一種益生細菌菌株、亦即長雙叉桿菌 (B/yVdoZmeierz’wm /ongwm)NCC3001(ATCC BAA-999,最初 144353.doc 201029583 由 Morinaga Mi丨k Industry Co. Ltd以名稱BB536提供)可增 加海馬回中BDNF表現。 壓力、焦慮及抑鬱已經證實與海馬區中之低BDNF含量 ,有關(Duman RS,Malberg J,Nakagawa S,D'Sa C. Neuronal plasticity and survival in mood disorders. Biol Psychiatry. 2000;48:732-73 9)。亦已對在正常變老期間BDNF及/或其受 體(TrkB.FL、TrkB.Tl及TrkB.T2)之表現有所降低作了描述 參 (Tapia-Arancibia L, Aliaga E, Silhol M, Arancibia S. Brain Res Rev. 2008,59(1):201-20)。在嬰兒中,許多生理學過 程在出生時並未完全成熟且僅在出生後頭幾個月或頭幾年 • 裏變得成熟。一些嬰兒及兒童之BDNF含量有可能會降 低。在該等情況下,BDNF含量低可能會導致睡眠紊亂, 及/或在嬰兒及兒童之特定情況下,導致無法發展成熟之 晝夜睡眠模式。在不希望受理論束縛之情況下,本發明者 咸信’可以此種方式解釋投與益生細菌菌株對睡眠障礙及 Φ 睡眠模式之有益影響。換言之,投與能夠增加海馬BDNF 表現之藥劑(諸如益生細菌菌株)因此可導致觀察到睡眠品 質之正常化及/或改善成熟睡眠模式之發展。 - 【實施方式】 • 在本說明書中,以下術語具有以下含義:_ 「嬰兒j意謂12個月以下之兒童; 「显生菌」意謂對宿主之健康或良好狀態具有有益影響之 微生物細胞製劑或微生物細胞組份。(Salminen s,
Ouwehand A. Benno γ·等人,「pr〇bi〇tics: h〇w should they 144353.doc 201029583 be definedj Trends Food Sci. Technol. 1999:10 107-10); 睡眠紊亂之嬰兒/幼小兒童」意謂會在夜裏覺醒且不能 在/又有父母察覺到其覺醒的情況下重回睡眠之嬰兒或幼小 兒童及7或不能自發睡眠之嬰兒或幼小兒童; 「幼小兒童」意謂一歲至三歲之間的兒童。 除非另有說明,否則所有百分比均以重量計。 益生細菌菌株可以藥物形式,例如以溶解於水中、等於 l〇el〇 Cfu之日劑量投與且以匙投與。或者,本發明之組合 物可為含量等於l〇e3與i〇el2 cfu/g(以乾重計)之間、更佳 為10e6與l〇e9 cfu/g之間的食品、營養組合物、營養藥 物、飲料、食品添加劑或動物食品。 例如,該組合物可為人乳強化劑、嬰兒配方、第二階段 配方(follow on f〇rmula)、成長乳粉、嬰兒縠類食品嬰兒 食品、優格(yogurt)、穀物棒、早餐穀類食品、甜點、冷 凍食rm、湯、動物食品、液體懸浮液、粉劑、錠劑、膠狀 物、糖果、營養組合物及/或補充劑,其目標在於為特定 病理病狀(或不希望有之生理病狀或生理病理病狀)提供幫 助,該等病狀諸如過敏症或不耐症、營養不良、炎症、危 重病、絞痛、外傷、感染、手術、注意力不足/過動症^ 抑鬱症、焦慮症、疲勞或壓力及其類似病狀,特別是在該 等特定病理病狀引起睡眠模式之紊亂時。 表述量荨於」包括細菌為活的、滅活的或死的或甚至 以諸如DNA或細胞壁物質之片段形式或以益生菌代謝物形 式存在的可能性。換言之,細菌數量係依據該數量之細菌 144353.doc 201029583 之群落形成能力來表述,其中認為所有細菌均為活細菌’ 而不管僅提供細菌代謝物或是細菌實際上為活的、滅活的 或死的、片段化的或任何或所有該等狀態之混合狀態。 ' 益生細菌菌株可為乳酸桿菌(lactobacillus)或雙叉桿菌 . (bifidobacterium)。較佳乳酸桿菌種之實例為鼠李糖乳酸 桿菌、副乾酷·乳酸桿菌 paracasez·)及羅伊氏乳酸桿菌
❶ rewieW)。尤其較佳之菌株為鼠李糖乳酸桿菌ATCC 53103、鼠李糖乳酸桿菌CGMCC 1.3724、羅伊氏乳酸桿菌 • ATCC 55730及羅伊氏乳酸桿菌DSM 17938。較佳雙叉桿菌 • 種之實例為乳雙叉桿菌、長雙叉桿 菌、短雙叉桿菌0reve)及嬰兒雙叉桿菌 。尤其較佳之菌株包括尤其由丹 麥Christian Hansen公司以商標Bbl2出售之乳雙叉桿菌 CNCM 1-3446、由日本Morinaga Milk Industry Co. Ltd.以 φ 商標BB536出售之長雙叉桿菌NCC3001(ATCC BAA-999)、 由Danisco以商標Bb-03出售之短雙叉桿菌菌株、由 Morinaga以商標Μ-16 V出售之短雙叉桿菌菌株、由lnstitut • Rosell(Lallemand)以商標R0070出售之短雙叉桿菌菌株及 . 由Procter & Gamble Co.以商標5. k/b«沿出售之嬰兒雙叉 桿菌菌株。益生菌可選自包含以下之列項:雙又桿菌屬、 乳酸桿菌屬、乳球菌屬(Lactococci)、腸球菌屬 (Enterococci)、鏈球菌屬(Streptococci)、丙酸桿菌屬 (Propionibacteria)、小球菌屬(Pediococci)、大腸桿菌屬 144353.doc 201029583 (Esc/zeric/zk co/ί)、德巴利酵母屬(Debaryomyces)、克魯 維酵母屬(Kluyveromyces)、酵母屬(Saccharoymces}、裂殖 酵母屬 (Schizosaccharomyces)、 接合酵母屬 (Zygosaccharomyces)、耶氏酵母屬(Yarrowia)、念珠菌屬 (Candida);以及以下之種:長雙叉桿菌、乳雙叉桿菌、動 物雙叉桿菌、短雙叉桿菌、嬰 兒雙叉桿菌、雙叉雙叉桿菌(万M/idwm)、青 春雙叉桿菌(万ad/o/escewih)、嗜酸乳酸桿菌 {Lactobacillus aczWop/nVws)、瑞士乳酸桿菌 /ze/vei/cws) ' 酷·蛋白乳酸桿菌(laciofeac^/ZMs case/)、副乾 酷乳酸桿菌、唾液乳酸桿菌(I<3cio&acz7/w«s ia/ivar/ws)、植 物乳酸桿菌(ZacioZ?<3ez·///^ 、醋酵乳酸桿菌 (Lactobacillus fermentum)、約氏乳敗桿儀(JLactobacilhis yo/msowz·/)、羅伊氏乳酸桿菌、加氏乳酸桿菌 gasser/)、鼠李糖乳酸桿菌、乳球菌亞種 {Lactococcus 以/?.)(諸如乳酸乳球菌(i^ciococcM·? /acib)、 乳脂乳球菌(ZaciococcM·? cremorb)、二丁酮乳球菌 (•LacioeoccM·? iiiaceij/aciz’·?))、摩腸球菌(五《ierococcws /aecz’wm)、糞腸球菌(五《ierococcws /aeca/b)、釀酒酵母 {Saccharomyces cerevisiae) 、 i\i ^ ^ {Saccharomyces 6ow/ar山·ζ·)、粟酒裂殖酵母(《Sd/zosacc/zaromyee·? pom6e)、 乳酸克魯_維酵母(幻wjveromyces /acik)、解脂耶氏酵母 (Tarrowia 或其混合物,較佳為選自由以下組成 之群:約氏乳酸桿菌(NCC5 33 ; CNCM 1-1225)、長雙叉桿 144353.doc -10- 201029583 菌(NCC490 ; CNCM 1-2170)、長雙叉桿菌(NCC2705 ; CNCM 1-2618)、長雙叉桿菌(NCC3001 ; ATCC BAA-999)、乳雙叉桿菌(NCC2818 ; CNCM 1-3446)、短雙又桿 * 菌(菌株A)、副乾酪乳酸桿菌(NCC2461 ; CNCM 1-2116)、 . 鼠李糖乳酸桿菌GG(ATCC53103)、鼠李糖乳酸桿菌 LPR(NCC4007 ; CGMCC 1.3724)、羅伊氏乳酸桿菌(ATCC 55730)、羅伊氏乳酸桿菌(DSM 17938)、屎腸球菌SF ^ 68(NCIMB10415)、布拉氏酵母及其混合物。 所選益生細菌菌株可根據此項技術中已知之任何適合方 法來培養且例如藉由冷凍乾燥或喷霧乾燥來製備以便添加 至本發明之藥物或營養組合物中。或者,細菌菌株可購自 諸如Christian Hansen及Morinaga之專門供應商且已以適合 於添加至營養組合物(諸如嬰兒配方)中之形式製備。 益生細菌適合之日劑量為10e3至10el2群落形成單位 (cfu),更佳為 10e7至 10el 1 cfu。 φ 本發明尤其適用於在嬰兒中誘發較成熟之睡眠模式,並 因此改善其睡眠品質且減少失眠之發生。在一項實施例 中,本發明係關於在嬰兒或幼小動物中減少睡眠障礙及/ • 或改善睡眠模式。 . 若欲處理該年齡組,則治療性營養組合物較佳為嬰兒配 方或較大嬰兒配方(follow-up formula)或用於寵物或動物 之相應產品。 在一項實施例中,睡眠品質或模式之改善的特徵在於、 包含或限於減少覺醒狀態之發生次數及/或減少睡眠斷續 144353.doc -11 - 201029583 現象(sleep fragmentation)及/或增加覺醒狀態之持續時間 (較好、較少斷續之睡眠/覺醒模式的指標)。 在一項實施例中,睡眠品質之改善的特徵在於在較長的 夜晚不存在不願意之覺醒情況以及睡眠比較安靜。 在一項實施例中’睡眠品質之改善的特徵在於入睡能力 較佳。 在一項實施例中,經歷睡眠模式紊亂(諸 睡眠、噩夢或失眠症)之個體的睡眠品質有改善 現將藉由實例來描述根據本發明使用之嬰兒配方之一般 組成。該嬰兒配方可含有含量不超過4 〇、3 〇或2 〇 g/i〇〇 kca卜較佳為^至二』g/1〇〇 kcal之蛋白質源。咸信蛋白質 類型對於本發明並非關鍵,其限制條件為滿足對必需胺基 酸含罝之最低要求且確保令人滿意之生長,但超過重量 /〇之蛋白質源為乳清為較佳的。在一項實施例中,蛋白質 含量在30%與8〇%乳清蛋白之間。因此,可使用基於乳 清、赂蛋白及其混合物之蛋白質源以及基於大豆之 源。就乳清蛋白而言,蛋白暂、、塔i、* 質源可以酸乳清或甜乳清或其 混合物為基礎且可包括任何 球蛋白。 斤需比例之…蛋白及β-乳 與經水解蛋白質之混人物;:7解的’或為完整蛋白 心 例如對於咸信面臨患上牛乳 敏^之風險㈣兒而[可“要提供部分水解之^ ^解程度介於2。/。與20%之間)。若 : 需要且如此項技術中所知進行水解過程。例;,可: 144353.doc 201029583 多個步驟藉由以酵素方式水解乳清部分來製備乳清蛋白水 解產物。若用作起始物質之乳清部分實質上不含乳糖,則 發現蛋白質在水解過程中發生少得多的離胺酸阻斷。此使 . 得離胺酸阻斷程度能夠自總離胺酸之約15重量。/。降低至不 . 到離胺酸之約10重量%(例如離胺酸之約7重量%),此極大 地改善了蛋白質源之營養品質。 嬰兒配方可含有碳水化合物源。可使用嬰兒配方中常見 • 之任何碳水化合物源,諸如乳糖、蔗糖、麥芽糊精、澱粉 及其混合物,但較佳之碳水化合物源為乳糖。碳水化合物 源較佳貢獻配方總能量的35%至65%。在本發明之一項較 佳貫施例中,碳水化合物包含稻米碳水化合物。在一項實 施例中,至少5%、至少1〇%、至少25%或至少5〇%、至少 70%、至少9〇%或約i〇〇%(w/w)之碳水化合物為稻米碳水化 合物。在本發明之情況下已顯示最小比例(總碳水化合物 之至少10% w/w)之稻米碳水化合物可為睡眠模式帶來實質 • 性益處。稻米碳水化合物之含量越高,改善之程度可越 大 了叙疋该效應與殿粉之存在(在稻米碳水化合物中)、 稻米碳水化合物之特殊性質及/或包含於稻米碳水化合物 中之其他化合物(澱粉除外)相關。包含稻米碳水化合物之 • 本發明之該營養組合物可尤其用於為兒童、幼小兒童或嬰 兒且尤其為具有睡眠模式障礙(例如由絞痛引起)之彼等兒 童、幼小兒童或嬰兒且更尤其為0與12個月之間的嬰兒設 計的嬰兒配方、較大嬰兒配方或食品之情況丁。 嬰兒配方可含有脂質源。脂質源可為適用於嬰兒配方之 144353.doc -13- 201029583 任何脂質或脂肪。較佳之脂肪源包括椋搁油、高油酸葵花 子油及高油酸紅花子油。亦可添加必需脂肪酸亞麻油酸及 α-次亞麻油酸,同樣可添加少量含有大量預形成之花生四 烯酸及二十二碳六烯酸的油,諸如魚油或微生物油。脂肪 含量較佳(諸如)總計貢獻配方總能量之30%至55%。脂肪 源的η-6與η-3脂肪酸之比率較佳為約5:1至約ΐ5:ι,例如約 8:1 至約 10:1。 本發明之嬰兒配方較佳另外含有量為〇 3 %至丨〇 %的至少 一種益菌助生質。益菌助生質為一種不可消化之食品成 伤其藉由選擇性刺激結賜中之一種或數種細菌的生長及/ 或活性來有益地影響宿主,且因此改善宿主健康。該等成 份在其在胃或小腸中不被分解及吸收之意義上而言係不可 消化的,且因此完好無損地轉運至結腸,在此處由有益細 菌選擇性地使該等成份醱酵。益菌助生質之實例包括某些 寡醣,諸如果寡醣(FOS)、牛乳寡醣(CM〇s)及半乳寡醣 (GOS)。可使用血菌助生質之組合,諸如與1 〇% 短鏈果券醣之組合(諸如以商標Raftil〇se⑧出售之產品)或與 10/〇菊糖之組合(諸如以商標RaftiHne⑧出售之產品)。在本 發明之情況下可使用之益菌助生質的其他實例包括自乳汁 或其他來源獲得之寡醣群,其視情況含有唾液酸、果糖、 海藻糖、半乳糖或甘露糖;較佳之益菌助生質為唾液酸寡 醣(SOS)、果寡醣(FOS)、半乳寡醣(G〇s)、異麥芽募醣 (IMO)、木寡醣(X〇s)、阿拉伯木寡醣(AX〇s)、甘露寡醣 (M0S)、大豆寡醣、葡萄糖基蔗糖(GS)、乳果寡醣(ls)、 144353.doc 14 201029583 唾液乳糖(SL)、海藻糖基乳糖(FL)、乳糖_N_新四糖 (LNNT)、乳果糖(la)、巴拉金糖寡醣(PAO)、麥芽寡醣、 其膠及/或水解產物、果膠、澱粉及/或其水解產物。 • 嬰兒配方亦可含有營養上有效量的在日常飲食中被視為 ' 必需的所有維生素及礦物質9已確立對某些維生素及礦物 質之最低要求。視情況存在於嬰兒配方中之礦物質、維生 素及其他營養物之實例包括維生素A、維生素B1、維生素 φ B2、維生素B6、維生素B12、維生素E、維生素κ、維生素 C、維生素D、葉酸、肌醇、菸酸、生物素、泛酸、膽 鹼、鈣、磷、碘、鐵、鎂、銅、鋅、錳、氯化物、鉀、 納、砸、絡、鉬、牛磺酸及L_肉鹼。礦物質通常係以鹽形 式添加。特定礦物質及其他維生素之存在及量應視預定嬰 兒群體而變化。 必要時’嬰兒配方可含有乳化劑及穩定劑,諸如大豆卵 鱗脂、檸檬酸單甘油酯與二甘油酯及其類似物。 # 嬰兒配方可視情況含有其他可具有有益效應之物質,諸 如纖維、乳鐵蛋白(lactoferrin)、核苷酸、核苷及其類似 物。 -最後’該配方可含有每公克嬰兒配方1〇e3至1〇el2 cfu、 -更佳為母公克配方1 〇e6至1 〇e9 cfu之益生細菌菌株。 上述嬰兒配方可以任何適合之方式來製備。舉例而言, 其可藉由將蛋白質、碳水化合物源及脂肪源以適當比例摻 合在一起來製備。若使用乳化劑,則可在此時包括乳化 劑。此時可添加維生素及礦物質,但通常係稍後進行添加 144353.doc 201029583 :::熱降解。可將任何親脂性維生素、乳化 物在播合之前溶解於脂肪源中。接著可將水、較佳為^ 订逆參透處理之水混人以形成液體混合物。 贼至―幫助該等成份之分散。可使用市售之= 态來形成液體混合物。接著例如分兩個階段將該液體混人 物均質化。 σ 接著可藉由例如在約5秒至約5分鐘内將液體混合物 加熱至約80〇C至約]<;η〇Γ +炫閉&以—山 、 C之範圍内的>m度來對液體混合物 進打熱處理以降低細菌負荷。此舉可藉由蒸汽注入、高壓 釜或藉由熱交換器(例如板式熱交換器)進行。 隨後,可例如藉由急驟冷卻使該液體混合物冷卻至約 60 C至約85 C °接著可例如分兩個階段再次將該液體混合 物均質化;第—階段在約10 MPa至約30 MPa下,且第二階 段在約2 MPa至約1G Mpa下。接著可將均f化混合物進— 步冷卻以添加任何熱敏性組份,諸如維生素及礦物質。此 ❹ 時適宜地調整均質化混合物之1?1^值及固體含量。 將均質化混合物轉移至適合乾燥裝置(諸如喷霧乾燥機 或冷凍乾燥機)中且轉變為粉末。粉末應具有不到約5重量 %之水分含量。在此階段可藉由乾式混合添加益生細菌菌 株。 在另項貫細*例中,組合物可為一種包括足以在個體中 達成所放應之量之益生細菌菌株的補充劑。此種投與形 式更適於兒童’但益生菌可以内部懸浮有益生細菌之油滴 形式投與嬰兒。該類產品之實例為含有由BioGaia AB, I44353.doc -16- 201029583
Sweden 出售之 L. reuteri DSM 17938 的 BioGaia益生菌滴 劑。 益生菌之日劑量較佳為10e3至1 Oe 12 cfu。對欲包括於補 ' 充劑中之益生菌之量應視該補充劑之投與方式而定作相應 . 選擇。舉例而言,若欲每天兩次投與該補充劑,則各補充 劑可含有5xl〇e2至5xl0ell cfu之益生菌。該補充劑可例如 呈錠劑、膠囊、片劑、栓劑、膠狀物或液體之形式。該補 φ 充劑可進一步含有保護性水膠體(諸如膠狀物、蛋白質、 改質澱粉)、黏合劑、成膜劑、囊封劑/材料、壁/殼材料、 基質化合物、包衣料、乳化劑、表面活性劑、增溶劑 (油、脂肪、蠟、卵磷脂等)、吸附劑、載劑、填充劑、辅 助化合物、分散劑、濕潤劑、加工助劑(溶劑)、助流劑、 味覺掩蔽劑、增重劑、膠凝劑及成膠劑。補充劑亦可含有 習知醫藥添加劑及佐劑、賦形劑及稀釋劑,包括(但不限 於)水、任何來源之明膠、植物膠、木質素磺酸鹽、滑 # 石、糖、澱粉、阿拉伯膠、植物油、聚伸烷二醇、芳香 劑、防腐劑、穩定劑、乳化劑、緩衝劑、潤滑劑、著色 劑、濕潤劑、填充劑及其類似物。 ' 另外’根據諸如USRDA之政府機構的建議,該補充劑可 - 含有適用於經口或腸内投藥之有機或無機載劑材料以及維 生素、礦物質、痕量元素及其他微量營養素。 在一項實施例中’本發明係關於在成人、大齡兒童(詳 吕之為3至12歲之間的兒童)、青少年或任何年齡段之人類 中減少睡眠障礙及/或改善睡眠模式。 144353.doc 17 201029583 在另一項實施例中,本發明係關於藉由使用益生菌來將 所描述之益處傳遞給寵物及其他動物(諸如貓、犬或馬)。 現將參考以下實例來進一步說明本發明:-實例1 以下提供根據本發明使用之嬰兒配方之組合物的一個實 例。該組合物僅係為了說明而給出。如下組合物之蛋白質 係來自乳清及酪蛋白(例如70%乳清及30%酪蛋白)。在另 一種選擇中,蛋白質僅來自乳清。 營養物 每 100 kcal 每公升 能量(kcal) 100 670 蛋白質(g) 1.83 12.3 脂肪(g) 5.3 35.7 亞麻油酸(g) 0.79 5.3 α-次亞麻油酸(mg) 101 675 乳糖(g) 11.2 74.7 益菌助生質(100%GOS)(g) 0.64 4.3 礦物質(g) 0.37 2.5 Na(mg) 23 150 K(mg) 89 590 Cl(mg) 64 430 Ca(mg) 62 410 P(mg) 31 210 Mg(mg) 7 50 Mn(pg) 8 50 Se(pg) 2 13 維生素A(pgRE) 105 700 維生素D(pg) 1.5 10 維生素E(mgTE) 0.8 5.4 維生素Kl(pg) 8 54 144353.doc • 18· 201029583 維生素C(mg) 10 67 維生素Bl(mg) 0.07 0.47 維生素B2(mg) 0.15 1.0 於酸(mg) 1 6.7 維生素B6(mg) 0.075 0.50 葉酸(Kg) 9 60 泛酸(mg) 0.45 3 維生素Β12(μ§) 0.3 2 生物素(pg) 2.2 15 膽驗(mg) 10 67 Fe(mg) 1.2 8 I〜g) 15 100 Cu(mg) 0.06 0.4 Zn(mg) 0.75 5 羅伊氏乳酸桿菌DSM17938 2.107 cili/g粉末 實例2 以下提供根據本發明使用之較大嬰兒配方之組合物的一 個實例。該組合物僅係為了說明而給出。如下組合物之蛋 白質係來自乳清及酪蛋白。在另一種選擇中,蛋白質僅來 自乳清。 較大嬰兒配方適於 6至12個月齡之嬰兒 營養物 每 100 kcal 每公升 能量(kcal) 100 630 蛋白質(g) 1.8 11.3 脂肪(g) 5.0 31.5 亞麻油酸(g) 0.75 4.7 α-次亞麻油酸(mg) 95 600 乳糖(g) 11.9 75 144353.doc -19- 201029583 益菌助生質(100%GOS)(g) 0.63 4.0 礦物質(g) 0.37 2.3 Na(mg) 25 158 K(mg) 80 504 Cl(mg) 65 410 Ca(mg) 60 378 P(mg) 33 208 Mg(mg) 7 44 Mn(pg) 5 32 Se(Hg) 3 19 維生素A(pgRE) 90 570 維生素D(pg) 1.5 9.5 維生素E(mgTE) 0.8 5.0 維生素Kl(pg) 8 50 維生素C(mg) 15 95 維生素Bl(mg) 0.1 0.6 維生素B2(mg) 0.1 0.6 终酸(mg) 0.5 3.2 維生素B6(mg) 0.06 0.4 葉酸(pg) 15 95 泛酸(mg) 0.8 5.0 維生素Β12(μ§) 0.2 1.3 生物素(pg) 2.0 12.6 膽驗(mg) 15 95 Fe(mg) 1.0 6.3 触) 15 95 Cu(mg) 0.06 0.4 Zn(mg) 0.9 5.7 BB536(=ATCC BAA-999,由Morinaga 寄存,源自 2.106cfli/g 粉末 Morinaga Milk Industry, Co., Ltd, Tokyo, Japan) 及/或 及/或 羅伊氏乳酸桿菌DSM 17938(源自Biogaia - BioGo:\2i 107 cfU/g粉末 AB, Sweden; 144353.doc -20- 201029583 實例3 以下提供根據本發明使用之較大嬰兒配方之組合物的一 個實例。該組合物僅係為了說明而給出。如下組合物之蛋 • 白質係來自乳清及酪蛋白(比率為50/50)。在另一種選擇 . 中,蛋白質僅來自乳清或70%(w/w)來自乳清。在如下實例 中,1 6%(w/w)之碳水化合物為稻米碳水化合物(在類似之 一個替代實例中,25%之碳水化合物為稻米碳水化合物)。 ^ 可向調配物中添加益菌助生質(例如GOS,0.5 g/100 kcal) ° 較大嬰兒配方適於 6至12個月齡之嬰兒 營養物 每 100 kcal 每公升 能量(kcal) 100 670 蛋白質(g) 2.2 14.6 脂肪⑻ 3.7 31.6 亞麻油酸(g) 0.76 5.1 α-次亞麻油酸(mg) 88 590 乳糖(g) 7.44 81.2 麥牙糊精(g) 2.1 14.2 澱粉(g) 2.59 17.3 益菌助生質(100%GOS)(g) 0.63 4.0 礦物質(g) 0.58 3.9 Na(mg) 39 158 K(mg) 113 760 Cl(mg) 73 490 Ca(mg) 105 700 P(mg) 66 440 144353.doc -21 - 201029583
Mg(mg) 11.4 76 維生素A(pgRE) 90 570 維生素Dbg) 1.5 9.5 維生素E(mgTE) 0.8 5.0 維生素Κ1(μ§) 8 50 維生素C(mg) 15 95 維生素Bl(mg) 0.1 0.6 維生素B2(mg) 0.1 0.6 於酸(mg) 0.5 3.2 維生素B6(mg) 0.06 0.4 葉酸(kg) 15 95 泛酸(mg) 0.8 5.0 維生素B12(pg) 0.2 1.3 生物素(pg) 2.0 12.6 膽驗(mg) 15 95 Fe(mg) 1.0 6.3 15 95 Cu(mg) 0.06 0.4 Zn(mg) 0.9 5.7 羅伊氏乳酸桿菌DSM 17938(源自Biogaia-BioGaiaAB, Sweden^ 及/或 鼠李糖乳酸桿菌CGMCC 1.3724 及/或 BB536(=ATCC BAA-999,由Morinaga 寄存,源 $ Morinaga Milk Industry, Co., Ltd, Tokyo, Japan) 107 cfij/g 粉末 及/或 106 cfb/g粉末 及/或 106 cfb/g粉末 實例4.益生菌對睡眠品質之影響 向懷孕大鼠施加之壓力會引起子代(亦即產前應激或PRS 動物)之睡眠品質變化,其類似具有紊亂睡眠模式之嬰兒 144353.doc -22- 201029583 與兒里及經歷不良睡眠品質及失眠症之成人所經歷的彼等 睡眠質變化。該等變化之特徵在於較淺之睡眠及覺醒發 生次數增多(亦即REM睡眠量增加,nrem之量減少及睡眠 ' 斷續現象增多(Dug〇vic,1999))。此模型已用於測試益生菌 - 之投與對睡眠品質的功效。 向PRS(亦即來自在妇娠期間經受束缚應激之母畜的子 代)及對照(亦即來自未受到干擾之母畜的子代)大鼠在深度 Φ 麻醉下植入慢性電極(chronic electrode)以用於額頂腦電圖 ( EG)眼電圖(E0G)及肌電圖(EMG)之多種波動記錄。所 有电極均連接至微型連接器上,且使用牙科用黏固劑固定 於顱骨。用多種波動記錄器(EEG_4414 A/K ; Nih〇n_ Khoden)記錄EEG、E〇G及EMG活動,其中輸出係與電腦 相連接以便對EEG作線上波譜分析。在植入電極之手術 後,將該等大鼠個別圈養在(直徑3〇 ,高 cm)中,且在2週内不受干擾。隨後在緊接著的“天内使該 • 料物適應於睡眠記錄程序。在此時藉ώ管飼法使其接受 安慰劑或兩種益生菌中之一者。在適應期結束時,自光照 階段起始時開始,記錄睡眠狀況,歷時24小時的時間。以 ' 30秒之分段(eP〇ch)對多種波動記錄作目測評分。彼等分段 • 被歸類為覺醒、NREM睡眠或REM睡眠。記錄該三種警覺 度狀態所耗費之時間量及各狀態發生之次數及持續時間。 研究以下各組: PRSr:接受i mL/天含有1〇9 cfu羅伊氏乳酸桿菌麵 17938(Bi〇Gaia益生菌滴劑,Bi〇Gaia AB,瑞典)之油滴劑的 144353.doc -23- 201029583 PRS動物。 PRSb :接受1 ml/天含有1010 cfu長雙叉桿菌NCC3001 (ATCC BAA-999,最初由 Morinaga Milk Industry Co. Ltd 提供),溶解於生理鹽水中之生理鹽水溶液的PRS動物。 PRSp :接受1 mL/天含有與羅伊氏乳酸桿菌產品相同之 油載劑但不含益生菌之滴劑的PRS動物。 對照組:接受1 mL/天含有與羅伊氏乳酸桿菌產品相同 之油載劑但不含益生菌之滴劑的對照動物。 結果展示於圖1及2中。正如所預期,相比於對照組,在 PRSp動物中安靜睡眠(NREM,圖1B)所耗費之時間量減少 且活動睡眠(REM,圖1C)所耗費之時間量增多,而在兩組 中覺醒狀態(圖1A)之持續時間類似。兩種益生菌之投與在 不影響覺醒狀態之持續時間的情況下使NREM及REM狀態 之持續時間正常化。相一致的是,在PRSp中覺醒(圖2 A)、 NREM(圖2B)及REM(圖2C)狀態在24小時内發生之次數多 於對照動物,此表明在PRSp組中睡眠斷續現象增多且覺醒 發生之次數較多。兩種益生菌使覺醒發生之次數及睡眠斷 續現象減少至對照組之程度。 總之,該資料表明益生菌之投與在動物模型中使睡眠模 式正常化且改善睡眠品質。由與安慰劑PRS組相比在益生 菌組中覺醒發生之次數減少且持續時間增加(資料未展示) 所表明,在益生菌組中較佳睡眠品質很可能使得在覺醒狀 態期間之警覺性得到改善。 144353.doc • 24·
Claims (1)
- 201029583 七、甲*月專利範圍: 種ι生細菌菌株之用途,其 動物中、沾, 丹你用於製造用以在人類或 中減少睡眠障礙及/或改善睡眠品 _ 物或營養紐合物。 賢次睡眠模式之藥 動物=1之用途其中該等人類或動物為嬰兒、幼小 動物或幼小兒童。 J 3.如請求項1或2中任一項之用途 歷不良品質之睡眠及/或失眠症 其中該等人類或動物經 4. 5. 6.青长項1或2之用途,其中該營養組合物在該等人類或 動物中誘發成熟睡眠模式或減少失眠發生之次數。 如明求項1或2之用途,其中該益生細菌菌株為乳酸桿菌 (laCt〇bacillus)或雙又桿菌(bifidobacterium)。 如凊求項5之用途’其中該乳酸桿菌為鼠李糖乳酸桿菌 7/Μί μ⑽繼叫種、副乾酪乳酸桿菌 種或羅伊氏乳酸桿菌 {Lactobacillus reuterf)後。 7.如請求項5之用途,其中該雙又桿菌為乳雙叉桿菌 (Bifidobacterium lactis)煃、長雙又桿壤⑻fid〇bacteri_ longum)種、短雙又样菌(B^dobacterium breve)種或婴兒 雙又夫干風(Bifidobacterium inf antis)後。 8·如s青求項1或2之用途,其中益生細菌之日劑量為ι〇3至 1012群落形成單位((^11),更佳為1〇7至1〇11(^11。 9.如請求項5之用途,其中益生細菌之曰劑量為1〇3至 群落形成單位(cfu),更佳為1 〇7至10n cfu。 144353.doc 201029583 :求項1或2之用途’其中該藥物或營養組合物中每公 樂物或组合物包含1〇3至1〇,2群落形成單位(咖)、更佳 二’ 1 〇至1 〇Π cfu之益生細菌。 u.=請求項5之用途,其中該藥物或營養组合物每公克華 或組合物包含形成單位(efu),更佳為 至1〇U cfu之益生細菌。 如月求項1或2之用途’其中該治療性營養組合物中該益 生細丨菌菌株含量為每公克乾藥物或乾營養組合物包含Μ 至1012 efu,更佳為每公克乾藥物或乾營養組合物 1〇6至 l〇9cfu。 13. 如請求項5之用途’其中該治療性營養組合物中該益生 細,菌株含量為每公克乾藥物或乾營養組合物包含ι〇3至 10 Cfu ’更佳為每公克乾藥物或乾營養組合物包含1〇6 至 109cfu〇 14. 如請求項1或2之用途’其中該藥物為補充劑且該益生細 菌菌株係以每單位劑量103至1〇l2 cfu之量存在。 •如請求項5之用途,其中該藥物為補充劑子且該益生細菌 菌株係以每單位劑量1〇3至1〇12 cfu之量存在。 丨6.如請求項丨或2之用途’其中該藥物或營子養組合物係呈人 乳強化劑、嬰兒配方、第二階段配方(f〇u〇w 〇n f〇_la)、成長乳粉、嬰兒穀類食品、嬰兒食品、優格 (yogurt)、榖物棒、早餐縠類食品、甜點、冷凍食品、 湯、寵物食品、液體懸浮液、粉劑、旋劑'膠狀物、糖 果、營養組合物或營養補充劑之形式,其目標在於為誘 144353.doc 201029583 發睡眠障礙之特定病理病狀提供幫助,該等病狀諸如過 敏症或食物不耐症、營養不良、慢性炎症、危重病、外 傷、感染、手術、注意力不足/過動症、抑鬱症、焦慮 - 症、疲勞或壓力。 . 17.如請求項5之用途,其中該藥物或營養組合物係呈人乳 強化劑、嬰兒配方、第二階段配方、成長乳粉、嬰兒穀 類食品、嬰兒食品、優格、縠物棒、早餐穀類食品、甜 φ 點、冷凍食品、湯、寵物食品、液體懸浮液、粉劑、錠 劑、膠狀物、糖果、營養組合物或營養補充劑之形式, 其目標在於為誘發睡眠障礙之特定病理病狀提供幫助, 該等病狀諸如過敏症或食物不耐症、營養不良、慢性炎 症、危重病、外傷、感染、手術、注意力不足/過動症、 抑鬱症、焦慮症、疲勞或壓力。 18.如請求項1或2之用途,其中該藥物或營養組合物可誘發 較成熟之睡眠模式。 ❹I9·如請求項1或2之用途,其中該營養組合物包含碳水化合 物’且其中該等碳水化合物包含稻米碳水化合物,較佳 至少10%(w/w)之該等碳水化合物為稻米碳水化合物。 ’ 2〇*如求項5之用途’其中該營養組合物為初生嬰兒配方 - 或較大(follow-up)嬰兒配方。 21. 如靖求項6之用途,其中該營養組合物為初生嬰兒配方 或較大嬰兒配方。 22. 如請求項12之用途,其中該營養組合物為初生嬰兒配方 或較大嬰兒配方。 144353.doc 201029583 23. 如請求項13之用途,其中該營養組合物為初生嬰兒配方 或較大嬰兒配方。 24. 如請求項1 9之用途,其中該營養組合物為初生嬰兒配方 或較大嬰兒配方。 144353.doc
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08168161 | 2008-11-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW201029583A true TW201029583A (en) | 2010-08-16 |
Family
ID=40785276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW098137248A TW201029583A (en) | 2008-11-03 | 2009-11-03 | A nutritional composition comprising probiotics and improving sleep patterns |
Country Status (16)
Country | Link |
---|---|
US (3) | US9034314B2 (zh) |
EP (2) | EP2352393A1 (zh) |
CN (2) | CN102960447A (zh) |
AU (1) | AU2009319257B2 (zh) |
BR (1) | BRPI0921617A2 (zh) |
CA (1) | CA2742476A1 (zh) |
CL (2) | CL2011000891A1 (zh) |
ES (1) | ES2771176T3 (zh) |
MX (1) | MX2011004142A (zh) |
MY (1) | MY160376A (zh) |
PH (1) | PH12014501749B1 (zh) |
PT (1) | PT2438821T (zh) |
RU (2) | RU2642301C9 (zh) |
TW (1) | TW201029583A (zh) |
WO (1) | WO2010060722A1 (zh) |
ZA (1) | ZA201206546B (zh) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010130663A1 (en) * | 2009-05-11 | 2010-11-18 | Nestec S.A. | Bifidobacterium longum ncc2705 (cncm i-2618) and immune disorders |
JP5923238B2 (ja) * | 2010-07-07 | 2016-05-24 | アサヒグループホールディングス株式会社 | 迷走神経活性化剤 |
AU2012221154B2 (en) * | 2011-02-23 | 2015-12-10 | Biogaia Ab | Indirect substrates for microorganisms metabolizing 1,2-propanediol |
CN103997899B (zh) | 2011-06-20 | 2016-04-20 | H.J.亨氏公司 | 益生菌组合物和方法 |
EP3704957A1 (en) * | 2012-09-14 | 2020-09-09 | Abbott Laboratories | Methods for increasing brain functionality using 2-fucosyl-lactose |
EP2708145B1 (en) | 2012-09-14 | 2016-05-04 | Abbott Laboratories | Nutritional compositions for use in methods for modulating corticosterone levels in psychologically stressed individuals |
DK3470074T3 (en) | 2013-05-10 | 2020-12-14 | Heinz Co Brands H J Llc | Probiotika |
GB201319538D0 (en) * | 2013-11-05 | 2013-12-18 | Optibiotix Health Ltd | Composition |
GB201319531D0 (en) | 2013-11-05 | 2013-12-18 | Optibiotix Health Ltd | Composition & methods of screening |
GB201319540D0 (en) | 2013-11-05 | 2013-12-18 | Optibiotix Health Ltd | Composition |
GB201319539D0 (en) | 2013-11-05 | 2013-12-18 | Optibiotix Health Ltd | Composition & methods of screening |
PL235821B1 (pl) * | 2014-11-04 | 2020-11-02 | Geo Poland Spolka Z Ograniczona Odpowiedzialnoscia | Wysokoprolinowy kompleks peptydowy do zastosowania w profilaktyce i wspomaganiu leczenia zaburzeń i stanów wymagających podwyższania i/lub modulacji poziomu neurotropowego czynnika pochodzenia mózgowego jako oznaczonego w osoczu krwi biomarkera i zawierający go preparat |
BR112018000934B1 (pt) * | 2015-08-31 | 2022-02-01 | Société des Produits Nestlé S.A. | Usos de bifidobacterium longum para tratar ou prevenir sintomas depressivos |
EP3344268A1 (en) * | 2015-08-31 | 2018-07-11 | Nestec S.A. | Methods and compositions using bifidobacterium longum to modulate emotional reactivity and treat or prevent sub-clinical mood disturbances |
CN107980002A (zh) * | 2015-08-31 | 2018-05-01 | 雀巢产品技术援助有限公司 | 使用长双岐杆菌优化母乳喂养的方法和组合物 |
WO2017131402A1 (ko) * | 2016-01-28 | 2017-08-03 | 경희대학교 산학협력단 | 면역조절 작용을 가는 사람 소화관 유래 신규 유산균 및 이의 용도 |
ES2954147T3 (es) | 2016-04-15 | 2023-11-20 | Baylor College Medicine | Lactobacillus reuteri mm4-1a para usar en el tratamiento o la prevención de trastornos del espectro autista |
CN109310716A (zh) * | 2016-07-01 | 2019-02-05 | 雀巢产品技术援助有限公司 | 用于预防和/或治疗哺乳动物的焦虑症及相关病症的包含益生菌的营养组合物 |
KR20180019474A (ko) | 2016-08-16 | 2018-02-26 | 주식회사 엠디헬스케어 | 락토바실러스 플란타룸 유래 소포를 포함하는 정신질환 예방 또는 치료용 조성물 |
EP3618843A1 (en) * | 2017-05-05 | 2020-03-11 | Société des Produits Nestlé S.A. | Treatment of infant colic |
WO2018215406A1 (en) * | 2017-05-24 | 2018-11-29 | Nestec S.A. | A nutritional composition for use to enhance attention and/or reduce impulsivity |
EP3634447A4 (en) * | 2017-06-02 | 2021-01-27 | University of Otago | USE OF LACTIC ACID BACTERIA TO TREAT OR PREVENT POSTNATAL DEPRESSION AND / OR POSTNATAL ANXIETY |
WO2019010254A1 (en) * | 2017-07-07 | 2019-01-10 | President And Fellows Of Harvard College | METHOD OF TREATING A DAMAGE INDUCED BY SLEEP |
ES2900380T3 (es) | 2017-08-11 | 2022-03-16 | Biocodex | Saccharomyces boulardii para el tratamiento de los trastornos del ánimo |
CA3074439A1 (en) | 2017-08-30 | 2019-03-07 | Shawn Talbott | Nutritional supplements affecting gut-brain-axis balance and mental wellness |
CN107712905A (zh) * | 2017-11-10 | 2018-02-23 | 无比滴(广东)药业有限公司 | 一种液体益生菌口服液 |
KR102250597B1 (ko) | 2017-11-20 | 2021-05-11 | 경희대학교 산학협력단 | 신규 유산균 및 이의 용도 |
WO2019098810A2 (ko) * | 2017-11-20 | 2019-05-23 | 경희대학교 산학협력단 | 신규 유산균 및 이의 용도 |
JP7303811B2 (ja) * | 2017-12-19 | 2023-07-05 | デュポン ニュートリション バイオサイエンシーズ エーピーエス | 認知的及び精神的健康のためのプロバイオティクス |
CA3085855A1 (en) * | 2017-12-19 | 2019-06-27 | Probiotical S.P.A. | Composition for use in the treatment and/or improvement of sleep and mood disorders |
TWI731209B (zh) * | 2018-01-09 | 2021-06-21 | 柯順議 | 益生菌組合物及其用途 |
CN116492376A (zh) | 2018-01-29 | 2023-07-28 | 精密生物集团有限公司 | 一种用于预防和治疗肠易激综合征的组合产品 |
CN111918663A (zh) | 2018-01-29 | 2020-11-10 | 精密生物集团有限公司 | 长双歧杆菌ncimb 41676 |
KR20200128672A (ko) | 2018-01-29 | 2020-11-16 | 프리시젼바이오틱스 그룹 리미티드 | 비피도박테리움 롱검 ncimb 41676 |
BR112020015599A2 (pt) | 2018-02-02 | 2021-01-05 | Kobiolabs, Inc. | Cepa de lactobacillus plantarum kbl396 e uso da mesma |
IT201800003128A1 (it) * | 2018-02-28 | 2019-08-28 | Propharma Soc A Responsabilita Limitata Semplificata | Composizione probiotica |
CN108186688B (zh) * | 2018-03-09 | 2021-03-16 | 华大精准营养(深圳)科技有限公司 | 一种促进睡眠的组合物 |
CN111989111B (zh) * | 2018-03-28 | 2024-03-22 | 森永乳业株式会社 | 睡眠促进用组合物及使用该睡眠促进用组合物的药物组合物和饮食品组合物 |
CN108823125A (zh) * | 2018-06-13 | 2018-11-16 | 山东巴元生物科技有限公司 | 一种治疗睡眠障碍益生菌制剂的生产方法及应用 |
HRP20221209T1 (hr) | 2018-07-24 | 2022-12-09 | Biogaia Ab | Odabir i upotreba bakterija koje povisuju razinu melatonina za smanjenje dojenačkih kolika |
CN108949640B (zh) * | 2018-08-22 | 2020-08-04 | 江南大学 | 短双歧杆菌ccfm1025、其发酵食品及其应用 |
WO2020078718A1 (en) | 2018-10-17 | 2020-04-23 | Frieslandcampina Nederland B.V. | Sleep-improving compositions |
CN109349645A (zh) * | 2018-10-30 | 2019-02-19 | 广州普维君健药业有限公司 | 益生菌组合物、保健食品及其制备方法和应用 |
US20220072107A1 (en) * | 2018-12-21 | 2022-03-10 | Societe Des Produits Nestle S.A. | Nutritional composition for inducing a feeling of satiety, a better sleep and/or limiting nocturnal awaking in infants or young children |
US20210352925A1 (en) * | 2019-02-04 | 2021-11-18 | N.V. Nutricia | Fermented formula with non digestible oligosaccharides for sleep improvement |
CN111297915B (zh) * | 2019-04-12 | 2021-11-23 | 首都医科大学附属北京友谊医院 | 治疗帕金森病快速眼动期睡眠行为障碍的益生菌组合物、制剂及用途 |
CN110200285A (zh) * | 2019-07-23 | 2019-09-06 | 河北一然生物科技有限公司 | 混合益生菌那曲4580(Nagqu 4580)在改善睡眠质量的食品中的应用 |
CN110339218A (zh) * | 2019-08-14 | 2019-10-18 | 牛占锋 | 一种益生菌组合物及其在改善睡眠紊乱中的应用 |
WO2021046450A1 (en) | 2019-09-04 | 2021-03-11 | Amare Global | Nutritional supplements and methods of supplementation affecting the endocannabinoid system |
WO2021046459A1 (en) | 2019-09-04 | 2021-03-11 | Amare Global | Nutritional supplements and methods of nutritional supplementation affecting heart/brain axis |
MX2022002767A (es) | 2019-09-04 | 2022-07-04 | Amare Global | Complementos nutricionales y métodos de complementación nutricional que afectan al humor y a la concentración en niños. |
CA3153409A1 (en) * | 2019-09-04 | 2021-03-11 | Amare Global | Nutritional supplements and methods of nutritional supplementation affecting microbiome metabolism |
JP6873291B1 (ja) * | 2020-02-05 | 2021-05-19 | 雪印メグミルク株式会社 | 睡眠促進用組成物及び組成物を含む食品、医薬品、飼料 |
CN115299609A (zh) * | 2022-03-21 | 2022-11-08 | 浙江臻叶茶业有限公司 | 一种具有改善睡眠功能的组合物及其制备方法 |
CN115025131B (zh) * | 2022-06-02 | 2023-06-30 | 广东南芯医疗科技有限公司 | 罗伊氏乳杆菌e9在制备缓解焦虑、改善睡眠药物中的应用 |
CN115226773A (zh) * | 2022-06-29 | 2022-10-25 | 湖北明慧健康科技有限责任公司 | 一种复合益生菌助眠固体饮料及其制备方法 |
CN116121130A (zh) * | 2022-12-23 | 2023-05-16 | 中科宜康(北京)生物科技有限公司 | 一种提高睡眠质量的复合益生菌发酵组合物及应用 |
CN116656549B (zh) * | 2023-05-25 | 2023-11-14 | 微康益生菌(苏州)股份有限公司 | 一种能够改善睡眠质量的益生菌剂及其应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPM864894A0 (en) * | 1994-10-07 | 1994-11-03 | Borody, Thomas Julius | Treatment of bowel-dependent neurological disorders |
US6444203B2 (en) * | 1999-12-20 | 2002-09-03 | Compagnie Gervais Danone | Administering bacteria to improve sleep |
AUPQ899700A0 (en) * | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
US20050100531A1 (en) * | 2002-06-13 | 2005-05-12 | John Bienenstock | Probiotic therapies |
JP4874532B2 (ja) * | 2004-08-25 | 2012-02-15 | 株式会社琉球バイオリソース開発 | 睡眠改善剤 |
JP2006160697A (ja) * | 2004-12-10 | 2006-06-22 | Kao Corp | 睡眠健康改善剤 |
JP4344827B2 (ja) * | 2005-11-28 | 2009-10-14 | 国立大学法人九州大学 | スキゾキトリウム属の微生物を用いた長鎖高度不飽和脂肪酸含有リン脂質の製造方法 |
ATE551063T1 (de) | 2006-02-15 | 2012-04-15 | Nestec Sa | Verwendung von bifidobacterium longum zur prophylaxe und behandlung von entzündungen |
US7374924B2 (en) * | 2006-06-05 | 2008-05-20 | Biogaia Ab | Use of selected lactic acid bacteria for reducing infantile colic |
US20070298013A1 (en) * | 2006-06-23 | 2007-12-27 | Altman Jay A | Animal Nutritional Supplement and Method |
JP2008137941A (ja) * | 2006-12-01 | 2008-06-19 | Mitsukan Group Honsha:Kk | 睡眠改善用組成物 |
US20080176305A1 (en) * | 2006-12-20 | 2008-07-24 | Kikkoman Corporation | Functional composition |
ES2381232T3 (es) * | 2007-02-28 | 2012-05-24 | Mead Johnson Nutrition Company | Procedimiento para el tratamiento o la prevención de la inflamación sistémica |
UA28995U (en) | 2007-09-24 | 2007-12-25 | Sanitary and hygienic product | |
EP2110028A1 (en) * | 2008-04-15 | 2009-10-21 | Nestec S.A. | Bifidobacterium longum and hippocampal BDNF expression |
-
2009
- 2009-10-29 EP EP09743896A patent/EP2352393A1/en active Pending
- 2009-10-29 WO PCT/EP2009/064276 patent/WO2010060722A1/en active Application Filing
- 2009-10-29 CA CA2742476A patent/CA2742476A1/en not_active Abandoned
- 2009-10-29 AU AU2009319257A patent/AU2009319257B2/en active Active
- 2009-10-29 PT PT121502280T patent/PT2438821T/pt unknown
- 2009-10-29 MY MYPI2011001597A patent/MY160376A/en unknown
- 2009-10-29 BR BRPI0921617-0A patent/BRPI0921617A2/pt not_active IP Right Cessation
- 2009-10-29 CN CN2012104593261A patent/CN102960447A/zh active Pending
- 2009-10-29 EP EP12150228.0A patent/EP2438821B1/en active Active
- 2009-10-29 RU RU2013137772A patent/RU2642301C9/ru active
- 2009-10-29 CN CN200980143393.9A patent/CN102202527B/zh active Active
- 2009-10-29 ES ES12150228T patent/ES2771176T3/es active Active
- 2009-10-29 RU RU2011122453/10A patent/RU2517616C2/ru active
- 2009-10-29 US US13/127,164 patent/US9034314B2/en active Active
- 2009-10-29 MX MX2011004142A patent/MX2011004142A/es active IP Right Grant
- 2009-11-03 TW TW098137248A patent/TW201029583A/zh unknown
-
2011
- 2011-04-20 CL CL2011000891A patent/CL2011000891A1/es unknown
-
2012
- 2012-07-12 CL CL2012001950A patent/CL2012001950A1/es unknown
- 2012-08-31 ZA ZA2012/06546A patent/ZA201206546B/en unknown
-
2014
- 2014-02-28 US US14/193,918 patent/US20140212389A1/en not_active Abandoned
- 2014-03-05 US US14/198,085 patent/US20140242050A1/en not_active Abandoned
- 2014-08-04 PH PH12014501749A patent/PH12014501749B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2517616C2 (ru) | 2014-05-27 |
CA2742476A1 (en) | 2010-06-03 |
CN102202527A (zh) | 2011-09-28 |
PH12014501749A1 (en) | 2016-01-18 |
PT2438821T (pt) | 2020-04-22 |
EP2438821A1 (en) | 2012-04-11 |
ES2771176T3 (es) | 2020-07-06 |
CN102960447A (zh) | 2013-03-13 |
AU2009319257B2 (en) | 2014-10-09 |
WO2010060722A1 (en) | 2010-06-03 |
RU2642301C2 (ru) | 2018-01-24 |
RU2642301C9 (ru) | 2018-06-27 |
US20140212389A1 (en) | 2014-07-31 |
CN102202527B (zh) | 2014-12-31 |
BRPI0921617A2 (pt) | 2015-08-18 |
PH12014501749B1 (en) | 2016-01-18 |
ZA201206546B (en) | 2022-03-30 |
US9034314B2 (en) | 2015-05-19 |
US20110206649A1 (en) | 2011-08-25 |
RU2013137772A (ru) | 2015-02-20 |
CL2012001950A1 (es) | 2013-01-11 |
US20140242050A1 (en) | 2014-08-28 |
EP2438821B1 (en) | 2020-01-15 |
EP2352393A1 (en) | 2011-08-10 |
RU2011122453A (ru) | 2012-12-10 |
MY160376A (en) | 2017-03-15 |
MX2011004142A (es) | 2011-05-25 |
CL2011000891A1 (es) | 2011-09-16 |
AU2009319257A1 (en) | 2010-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2517616C2 (ru) | Питательная композиция, включающая пробиотики и улучшающая характер сна | |
EP3478306B1 (en) | Nutritional composition comprising a probiotic for the prevention and/or treatment of anxiety disorders and depression in a mammal | |
Singh et al. | Probiotics: A review | |
CN101299934B (zh) | 用于促进追赶生长的营养制剂 | |
RU2567660C2 (ru) | Bifidobacterium longum ATCC BAA-999 (BL999) И КОНТРОЛИРОВАНИЕ ВЕСА | |
TW200948372A (en) | Bifidobacterium longum and hippocampal BDNF expression | |
BRPI0707937A2 (pt) | uso de bifidobacterium longum para a prevenÇço e tratamento de inflamaÇço | |
BR112018000934B1 (pt) | Usos de bifidobacterium longum para tratar ou prevenir sintomas depressivos | |
JP7407195B2 (ja) | アレルギー性疾患の治療のためのプロバイオティクスの組み合わせ | |
JP7296454B2 (ja) | 炎症関連胃腸障害の処置のためのプロバイオティクスの組み合わせ | |
US20200315235A1 (en) | Normalization of the Intestinal Microbiota Composition in Infants or Toddlers Fed with an Amino Acid-Based Nutritional Composition | |
JP2023133435A (ja) | 睡眠促進用組成物並びに該睡眠促進用組成物を用いた医薬品組成物及び飲食品組成物 | |
AU2014221272B2 (en) | A nutritional composition comprising probiotics and improving sleep patterns | |
CN114745966A (zh) | 用于减少婴儿和幼儿的疼痛和/或疼痛感的组合物 | |
TW201333193A (zh) | 用於發育腸神經系統之洛德乳桿菌(Lactobacillus reuteri)DSM 17938 |